Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Sartorius Stedim Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Sartorius Stedim Biotech şirketinin toplam hissedar öz sermayesi €3.9B ve toplam borcu €2.8B olup, bu da borç-öz sermaye oranını 71.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €8.1B ve €4.1B dir. Sartorius Stedim Biotech 'in FAVÖK'ü €416.9M faiz karşılama oranı 2.6 dur. Şirketin €454.1M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

71.7%

Borç/özkaynak oranı

€2.81b

Borç

Faiz karşılama oranı	2.6x
Nakit	€454.10m
Eşitlik	€3.92b
Toplam yükümlülükler	€4.14b
Toplam varlıklar	€8.07b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 56S1 'nin kısa vadeli varlıkları ( €1.7B ) kısa vadeli yükümlülüklerini ( €873.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: 56S1 'un kısa vadeli varlıkları ( €1.7B ) uzun vadeli yükümlülüklerini ( €3.3B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 56S1 'nin net borç/öz sermaye oranı ( 60.1% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 56S1 şirketinin borç/öz sermaye oranı son 5 yılda 11% seviyesinden 71.7% seviyesine yükseldi.

Borç Kapsamı: 56S1 'nin borcu işletme nakit akışı ( 25.1% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 56S1 'in borcuna ilişkin faiz ödemeleri EBIT ( 2.6 x kapsam) tarafından iyi karşılanmıyor.

Sartorius Stedim Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Second quarter 2024 earnings released: €0.011 loss per share (vs €1.44 profit in 2Q 2023)

Now 22% overvalued

Investor sentiment deteriorates as stock falls 16%

First quarter 2024 earnings released: EPS: €0.58 (vs €1.21 in 1Q 2023)

Upcoming dividend of €0.69 per share

Dividend of €0.69 announced

New minor risk - Profit margin trend

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

First quarter 2023 earnings released: EPS: €1.21 (vs €2.93 in 1Q 2022)

Upcoming dividend of €1.44 per share at 0.5% yield

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021)

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021

Upcoming dividend of €1.26 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Recommends Dividend

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020)

Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021

First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020)

Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021

Sartorius Stedim Biotech Increases Earnings Guidance for 2021

Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019)

Revenue misses expectations

New 90-day high: €416

New 90-day high: €366

Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o.

New 90-day high: €329

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021

New 90-day high: €313

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million.

New 90-day high - €303

New 90-day high - €273

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

New 90-day high - €259

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin